Pfizer’s (PFE) “Buy” Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Pfizer (NYSE:PFE) in a report published on Wednesday,Benzinga reports.

A number of other analysts also recently weighed in on the stock. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. UBS Group dropped their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Up 0.5 %

Shares of Pfizer stock opened at $25.74 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The business has a 50-day moving average price of $26.24 and a 200-day moving average price of $27.15.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PFE. PKO Investment Management Joint Stock Co acquired a new position in shares of Pfizer during the fourth quarter worth $2,096,000. Northstar Financial Companies Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $854,000. Wealthedge Investment Advisors LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $207,000. Lighthouse Financial LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $301,000. Finally, Anchor Pointe Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at approximately $281,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.